Investigational New Drugs

, Volume 37, Issue 5, pp 1006–1013 | Cite as

Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma

  • Yi Luo
  • Anqi Zeng
  • Aiping Fang
  • Linjiang Song
  • Chen Fan
  • Chenjuan Zeng
  • Tinghong Ye
  • Hao Chen
  • Chongqi Tu
  • Yongmei XieEmail author


Osteosarcoma is the most common primary malignancy of bone and characterized by an appendicular primary tumor with a high rate of metastasis to the lungs. Unfortunately, there is no effective strategy to treat osteosarcoma in current clinical practice. In this study, the anticancer effects and potential mechanisms of nifuroxazide, an oral nitrofuran antibiotic, on two osteosarcoma cell lines were investigated. The results of the antiproliferative activity in vitro showed that nifuroxazide inhibited cell proliferation of UMR106 and MG63 cells in a dose- and time-dependent manner. Interestingly, nifuroxazide showed low toxicity to non-tumor cells (HEK 293 T). In addition, ROS-mitochondrial mediated apoptosis was observed after treatment of nifuroxazide. Moreover, nifuroxazide could significantly inhibit osteosarcoma cells migration and invasion via p-Stat3, MMP-2 and MMP-9 mediated signaling pathway. Taken together, our results suggested that nifuroxazide could be a promising agent for osteosarcoma treatment by inhibiting cell proliferation, inducing cell apoptosis and impairing cell migration and invasion.


Osteosarcoma Nifuroxazide Apoptosis Anti-proliferation Anti-metastasis 



This work was supported by the Support Program for Science and Technology of Sichuan Province (2017SZ0106).

Compliance with ethical standards

Conflict of interest

The authors confirm that they have no conflict of interest with the content of this article.

Ethical approval

This article does not contain studies with human participants or animals performed by any of the authors.


  1. 1.
    Whelan JS, Davis LE (2018) Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol 36:188–193CrossRefGoogle Scholar
  2. 2.
    Wang W, Zhao HF, Yao TF, Gong H (2018) Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. Investig New Drugs.
  3. 3.
    Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML (2009) Juvenile myelomonocytic leukemia: a report from the 2nd international JMML symposium. Leuk Res 33:355–362CrossRefGoogle Scholar
  4. 4.
    Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F et al (2009) Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 125:2586–2594CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM et al (2018) Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med 24:178–185Google Scholar
  6. 6.
    Geller DS, Gorlick R (2010) Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8:705–718Google Scholar
  7. 7.
    Tomita K, Kawahara N, Murakami H, Demura S (2006) Total en bloc spondylectomy for spinal tumors: improvement of the technique and its associated basic background. J Orthop Sci 11:3–12CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Deng ZP, Ding Y, Puri A, Wang EH, Gulia A, Durban C et al (2015) The surgical treatment and outcome of nonmetastatic extremity osteosarcoma with pathological fractures. Chin Med J 128:2605–2608CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Biazzo A, De Paolis M (2016) Multidisciplinary approach to osteosarcoma. Acta Orthop Belg 82:690–698Google Scholar
  10. 10.
    Akagunduz OO, Kamer SA, Kececi B, Demirag B, Oniz H, Kantar M et al (2016) The role of radiotherapy in local control of nonextremity Ewing sarcomas. Tumori 102:162–167CrossRefGoogle Scholar
  11. 11.
    Wang CC, Jing JH, Cheng L (2018) Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma. Investig New Drugs 36:1116–1132CrossRefGoogle Scholar
  12. 12.
    Ritter J, Bielack SS (2010) Osteosarcoma. Ann Oncol 21(Suppl 7):vii320–vii325Google Scholar
  13. 13.
    Xue HQ, Li J, Xie HZ, Wang YD (2018) Review of drug repositioning approaches and resources. Int J Biol Sci 14:1232–1244CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Würth R, Thellung S, Bajetto A, Mazzanti M, Florio T, Barbieri F (2016) Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov Today 21:190–199CrossRefGoogle Scholar
  15. 15.
    Shim JS, Liu JO (2014) Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 10:654–663CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Zhu Y, Ye T, Yu X, Lei Q, Yang F, Xia Y et al (2016) Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep 6:20253CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Ye TH, Yang FF, Zhu YX, Li YL, Lei Q, Song XJ et al (2017) Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death Dis 8:e2534CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Yang F, Hu M, Lei Q, Xia Y, Zhu Y, Song X et al (2015) Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis 6:e1701CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Zhang T, Li J, Dong Y, Zhai D, Lai L, Dai F et al (2012) Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat 135:445–458CrossRefGoogle Scholar
  20. 20.
    Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu L et al (2014) The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PLoS One 9:e85887CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Thandapani P, Aifantis I (2017) Apoptosis, up the ante. Cancer Cell 32:402–403CrossRefGoogle Scholar
  22. 22.
    Hahn WC (2004) Cancer: surviving on the edge. Cancer Cell 6:215–222CrossRefGoogle Scholar
  23. 23.
    Slee EA, Adrain C, Martin SJ (2001) Executioner caspase-3, −6, and −7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276:7320–7326CrossRefGoogle Scholar
  24. 24.
    Benhar M, Forrester MT, Hess DT, Stamler JS (2008) Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320:1050–1054CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Wang C, Youle RJ (2009) The role of mitochondria in apoptosis. Annu Rev Genet 43:95–118CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Singh PK, Roukounakis A, Frank DO, Kirschnek S, Das KK, Neumann S et al (2017) Dynein light chain 1 induces assembly of large Bim complexes on mitochondria that stabilize Mcl-1 and regulate apoptosis. Genes Dev 31:1754–1769CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Pyakurel A, Savoia C, Hess D, Scorrano L (2015) Extracellular regulated kinase phosphorylates mitofusin 1 to control mitochondrial morphology and apoptosis. Mol Cell 58:244–254CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Bhola PD, Letai A (2016) Mitochondria-judges and executioners of cell death sentences. Mol Cell 61:695–704CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J et al (2015) A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov 5:920–931CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Ellegast J, Barth TF, Schulte M, Bielack SS, Schmid M, Mayer-Steinacker R (2011) Metastasis of osteosarcoma after 16 years. J Clin Oncol 29:e62–e66CrossRefGoogle Scholar
  31. 31.
    Lu J, Song G, Tang Q, Zou C, Han F, Zhao Z et al (2015) IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-kappaB signaling. J Clin Invest 125:1839–1856CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Hattori H, Yamamoto K (2012) Lymph node metastasis of osteosarcoma. J Clin Oncol 30:e345–e349CrossRefGoogle Scholar
  33. 33.
    Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67–68CrossRefGoogle Scholar
  34. 34.
    Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM (2007) Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 52:1388–1396CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Orthopedics, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  2. 2.State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center for BiotherapySichuan UniversityChengduPeople’s Republic of China
  3. 3.Sichuan Academy of Chinese Medicine SciencesChengduPeople’s Republic of China
  4. 4.School of Medical and Life SciencesChengdu University of Traditional Chinese MedicineChengduPeople’s Republic of China
  5. 5.Department of Pharmaceutical Sciences, College of PharmacyUniversity of Tennessee Healthy Science CenterMemphisUSA

Personalised recommendations